Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions

Executive Summary

WellPoint's updated formulary submission guidelines aim to give drug companies more detailed advice on submitting information on a drug's cost-effectiveness and its impact on pharmacy and medical budgets, as well as its effectiveness in improving patients' quality of life

You may also be interested in...



CMS Guidance On Desired Data Might Meet The Goals Of Parallel Review More Reasonably, Former Official Gottlieb Suggests

AEI's Scott Gottlieb, a former official at FDA and CMS, offers his insights into the proposed parallel review program during Avalere conference.

WellPoint Plans CER Guidance, Building On Progress With Outcomes Data

WellPoint believes its discussions with drug manufacturers about patient outcomes have improved in the 18 months since it published technology assessment criteria focusing on that topic. Now it is updating its criteria to include how to submit results from comparative effectiveness research

WellPoint Plans CER Guidance, Building On Progress With Outcomes Data

WellPoint believes its discussions with drug manufacturers about patient outcomes have improved in the 18 months since it published technology assessment criteria focusing on that topic. Now it is updating its criteria to include how to submit results from comparative effectiveness research

Related Content

UsernamePublicRestriction

Register

PS050277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel